Predictors of mortality in patients with bacteremia of unknown source due to extended spectrum beta-lactamase producing Escherichia coli

Journal of Chemotherapy

Volumn 21, Issue 4, 2009, Pages 448-451

  Metan, Gokhan ^a   Altinbas, A ^b   Zarakolu, P ^b   Yildiz, O ^a   Cetinkaya Sardan, Y ^b   Sumerkan, B ^a   Hascelik, G ^b  

^a ERCIYES UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD CULTURE; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 70349197592     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.4.448     Document Type: Article

References (19)

1. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteremia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60(5):913-20. (Pubitemid 47617735)
2. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49(2):760-766
3. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization Clin Infect Dis 2002;34(12):1600-1606
4. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16(3): 128-140
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 14th informational supplement M100-S14. Wayne, Pa, USA: National Committee for Clinical Laboratory Standards; 2004.
6. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 2000.
7. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004 ;48(12):4574-4581
8. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007;55(3):254-259 (Pubitemid 47244918)
9. Metan G, Zarakolu P, Cakir B, Hascelik G, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2005;26(3):254-257 (Pubitemid 41219613)
10. Henshke-Bar-Meir R, Yinnon AM, Rudensky B, Attias D, Schlesinger Y, Raveh D. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae. Infection 2006;34(2):66-74. (Pubitemid 43747436)
11. O'Hara CM. Manual and automated instrumentation for identification of Enterobacteriaceae and other aerobic gram-negative bacilli. Clin Microbiol Rev 2005; 18(1):147-162.
12. Donay JL, Mathieu D, Fernandes P, Preqermanin C, Bruel P, Warqnier A, et al. Evaluation of automated phoenix system for potential routine use in the clinical microbiology laboratory. J Clin Microbiol 2004; 42(4):1542-1546 (Pubitemid 38500793)
13. Snyder JW, Munier GK, Johnson CL. Direct comparison of BD phoenix system with MicroScan Walkaway system for identification and antimicrobial susceptibility testing of Enterobacteriaceae and nonfermentative gram-negative organisms. J Clin Microbiol 2008; 46(7):2327-2333
14. Doi Y, Paterson DL. Detection of plasmid mediated class C beta-lactamases. Int J Antimicrob Agents 2007;11:191-197
15. Ding H, Yang Y, Lu O, Wang Y, Chen C, Deng L, et al. The prevalence of plasmid mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumonia from five children's hospital in China. Eur J Clin Microbiol Infect Dis 2008; 27(10):915-921
16. Song W, Kim JS, Kim HS, Yong D, Jeong SH, Park MJ, et al. Increasing trend in the prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at Korean University Hospital from 2002 to 2004. Diagn Microbiol Infect Dis 2006; 55(3):219-224.
17. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22(1):161-182.
18. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686
19. Pitout JD, Le P, Church DL, Gregson DB, Laupland KB. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/ tazobactam. Int J Antimicrob Agents 2008;32:333-338